Ribitol-
phosphate modification is crucial for the functional maturation of α-
dystroglycan. Its dysfunction is associated with
muscular dystrophy,
cardiomyopathy, and central nervous system abnormalities; however, no effective treatments are currently available for diseases caused by
ribitol-
phosphate defects. In this study, we demonstrate that
prodrug treatments can ameliorate
muscular dystrophy caused by defects in
isoprenoid synthase domain containing (ISPD), which encodes an
enzyme that synthesizes
CDP-ribitol, a donor substrate for
ribitol-
phosphate modification. We generated skeletal muscle-selective Ispd conditional knockout mice, leading to a pathogenic reduction in
CDP-ribitol levels, abnormal glycosylation of α-
dystroglycan, and severe
muscular dystrophy. Adeno-associated virus-mediated gene replacement experiments suggested that the recovery of
CDP-ribitol levels rescues the ISPD-deficient pathology. As a
prodrug treatment strategy, we developed a series of membrane-permeable
CDP-ribitol derivatives, among which tetraacetylated
CDP-ribitol ameliorated the dystrophic pathology. In addition, the
prodrug successfully rescued abnormal α-
dystroglycan glycosylation in patient fibroblasts. Consequently, our findings provide proof-of-concept for supplementation
therapy with
CDP-ribitol and could accelerate the development of therapeutic agents for
muscular dystrophy and other diseases caused by glycosylation defects.